NASDAQ:GBT - Global Blood Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $52.47 -0.42 (-0.79 %) (As of 03/19/2019 03:06 PM ET)Previous Close$52.89Today's Range$51.57 - $52.9152-Week Range$30.15 - $54.88Volume15,536 shsAverage Volume723,725 shsMarket Capitalization$2.96 billionP/E Ratio-15.40Dividend YieldN/ABeta2.13 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California. Receive GBT News and Ratings via Email Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GBT Previous Symbol CUSIPN/A CIK1629137 Webwww.gbt.com Phone650-741-7700Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio14.38Price-To-Earnings Trailing P/E Ratio-15.40 Forward P/E Ratio-13.49 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.97 per share Price / Book4.78Profitability EPS (Most Recent Fiscal Year)($3.41) Net Income$-174,190,000.00 Net MarginsN/A Return on Equity-33.35% Return on Assets-31.10%Miscellaneous Employees171 Outstanding Shares56,320,000Market Cap$2.96 billion Next Earnings Date5/6/2019 (Estimated) OptionableOptionable Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions What is Global Blood Therapeutics' stock symbol? Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT." How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics Inc (NASDAQ:GBT) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.88) by $0.05. During the same quarter last year, the company earned ($0.95) earnings per share. View Global Blood Therapeutics' Earnings History. When is Global Blood Therapeutics' next earnings date? Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Global Blood Therapeutics. What price target have analysts set for GBT? 14 brokers have issued 1-year target prices for Global Blood Therapeutics' stock. Their predictions range from $57.00 to $150.00. On average, they anticipate Global Blood Therapeutics' share price to reach $88.2308 in the next year. This suggests a possible upside of 68.9% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics. What is the consensus analysts' recommendation for Global Blood Therapeutics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics. What are Wall Street analysts saying about Global Blood Therapeutics stock? Here are some recent quotes from research analysts about Global Blood Therapeutics stock: 1. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/4/2019) 2. William Blair analysts commented, "We continue to view the stock as substantially de-risked with the completion of 24 weeks of therapy in the additional 118 enrolled patients in the Phase III HOPE study , publication of the HOPE Part A data set, and a pre-NDA meeting update in the first half as well as potential Subpart H filing in the second half as key catalysts for shares this year . We also see the company as a potential takeout candidate given the significant unmet medical need in sickle cell disease, the impressive data shown in patients with or without concomitant hydroxyurea, and the alignment of a once-daily , oral therapy dosed (potentially) in perpetuity with the large pharma commercial model. GBT remains our top pick for 2019." (1/30/2019) 3. Cantor Fitzgerald analysts commented, "Based on the existing clinical data, we believe voxelotor offers a compelling treatment option in SCD that lacks disease-modifying therapies. $96 price target is based on the combination of our estimate of the NPV of future cash flows from voxelotor in SCD, worth approximately $4.6 billion ($88/share), and our estimate of YE cash of $440 million ($8/share)." (10/17/2018) 4. HC Wainwright analysts commented, "We continue to expect voxelotor in conjunction with HU to become the standard-of-care, especially in younger patients, which could make these patients asymptomatic much like SCD-trait subjects. Our Buy rating and price target of $125 are based on a DCF analysis, derived using a beta of 1.40, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.9%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $$60K (increased from $75K and $50K) U.S." (8/23/2018) Has Global Blood Therapeutics been receiving favorable news coverage? News articles about GBT stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Global Blood Therapeutics' key competitors? Some companies that are related to Global Blood Therapeutics include Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Catalent (CTLT) and Nektar Therapeutics (NKTR). What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Exelixis (EXEL), Adobe (ADBE), Vertex Pharmaceuticals (VRTX), Netflix (NFLX), Square (SQ), AbbVie (ABBV) and Intel (INTC). Who are Global Blood Therapeutics' key executives? Global Blood Therapeutics' management team includes the folowing people: Dr. Ted W. Love, Pres, CEO & Director (Age 60)Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)Mr. Peter Radovich, Sr. VP of Operations (Age 41)Dr. Hing Sham, Sr. VP of Research (Age 67) When did Global Blood Therapeutics IPO? (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. Who are Global Blood Therapeutics' major shareholders? Global Blood Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.95%), Perceptive Advisors LLC (10.39%), BlackRock Inc. (8.09%), Bank of America Corp DE (4.87%), Great Point Partners LLC (2.26%) and Geode Capital Management LLC (1.19%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics. Which institutional investors are selling Global Blood Therapeutics stock? GBT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, grace capital, Casdin Capital LLC, Candriam Luxembourg S.C.A., Hudson Bay Capital Management LP, Tekla Capital Management LLC, Highbridge Capital Management LLC and MetLife Investment Advisors LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Jung Choi and Lesley Ann Calhoun. View Insider Buying and Selling for Global Blood Therapeutics. Which institutional investors are buying Global Blood Therapeutics stock? GBT stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Bank of America Corp DE, FMR LLC, Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Bank of New York Mellon Corp and Perceptive Advisors LLC. View Insider Buying and Selling for Global Blood Therapeutics. How do I buy shares of Global Blood Therapeutics? Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Global Blood Therapeutics' stock price today? One share of GBT stock can currently be purchased for approximately $52.23. How big of a company is Global Blood Therapeutics? Global Blood Therapeutics has a market capitalization of $2.94 billion. The company earns $-174,190,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe. What is Global Blood Therapeutics' official website? The official website for Global Blood Therapeutics is http://www.gbt.com. How can I contact Global Blood Therapeutics? Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected] MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 408 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 647MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What are retained earnings?